Literature DB >> 931204

Tamoxifen (antiestrogen) therapy in advanced breast cancer.

D T Kiang, B J Kennedy.   

Abstract

Fifty-nine postmenopausal women with advanced breast cancer were treated with tamoxifen (antiestrogen), 20 mg orally twice a day for at least 2 months. They had been previously treated with other types of hormonal therapy or intensive chemotherapies, or both. Nineteen of the 59 patients (32%) had either a complete response (seven patients) or partial response (12 patients). The median duration of response was 9+ months. Tumors containing estrogen receptors and those that responded to previous hormonal manipulation tended to respond to tamoxifen (60% and 69%, respectively). Patients with receptor-negative tumor or with a history of failure of previous hormonal treatments did not respond to tamoxifen therapy. Tamoxifen is effective against advanced breast cancer. Side effects of the treatment were mild.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 931204     DOI: 10.7326/0003-4819-87-6-687

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  27 in total

1.  Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.

Authors:  B M Sherman; F K Chapler; K Crickard; D Wycoff
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

2.  Profile of V. Craig Jordan.

Authors:  Sujata Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-16       Impact factor: 11.205

3.  Tamoxifen in the management of metastatic cancer of the breast.

Authors:  L A Cone; N E Romanoff; N A Helm
Journal:  West J Med       Date:  1979-09

Review 4.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

5.  Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.

Authors:  V Craig Jordan
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.

Authors:  E Petru; D Schmähl
Journal:  Klin Wochenschr       Date:  1987-10-15

Review 7.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

8.  Update in cancer chemotherapy: general considerations and breast cancer, Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-08       Impact factor: 1.798

9.  Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients.

Authors:  E M Mora; S E Singletary; A U Buzdar; D A Johnston
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

Review 10.  Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.